Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer

F. Gainor, Justin; Dardaei, Leila; Yoda, Satoshi; Friboulet, Luc; Leshchiner, Ignaty; Katayama, Ryohei; Dagogo‐Jack, Ibiayi; M. Gadgeel, Shirish; R. Schultz, Katherine; Singh, Manrose; Chin, Emily; Parks, Melissa; Lee, Dana; H. DiCecca, Richard; L. Lockerman, Elizabeth; G. Huynh, Tiffany; Logan, Jennifer; L. Ritterhouse, Lauren; P. Le, Long; Muniappan, Ashok; R. Digumarthy, Subba; L. Channick, Colleen; Keyes, Colleen; Getz, Gad; Dias‐Santagata, Dora; S. Heist, Rebecca; K. Lennerz, Jochen; V. Sequist, Lecia; H. Benes, Cyril; John Iafrate, A.; Mino–Kenudson, Mari; A. Engelman, Jeffrey; T. Shaw, Alice

doi:10.1158/2159-8290.cd-16-0596

Public

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer

Published in Cancer Discovery • Jul 18, 2016

Authors:

Justin F. Gainor

Leila Dardaei

Satoshi Yoda

Abstract

Abstract Advanced, anaplastic lymphoma kinase (ALK)–positive lung cancer is currently treated with the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK inhibitors (e.g., ceritinib and alectinib) upon progression. Second-generation inhibitors are generally effe...

Subject

Crizotinib

Ceritinib

Anaplastic lymphoma kinase

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!